Adnexus Therapeutics

Compound Therapeutics Becomes AdNexus Therapeutics

Compound Therapeutics Becomes AdNexus Therapeutics

June 21, 2006

Company Continues to Advance the AdNectin Therapeutic Class

Waltham, MA, June 21, 2006– Compound Therapeutics, Inc., a private biotechnology company focused on development of medicines based on AdNectins™, today announced it has changed its name to Adnexus Therapeutics, Inc.. The company’s new website will be www.adnexustx.com

Adnexus Therapeutics

First AdNectin Therapeutic, CT-322, Clears FDA IND Review to Start Clinical Trials

First AdNectin Therapeutic, CT-322, Clears FDA IND Review to Start Clinical Trials

June 21, 2006

Anti-Cancer Therapeutic is a First in a Broadly Applicable, Innovative Class of Targeted Therapeutics

Acceleron Pharma, Inc.

Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss

Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss

June 21, 2006

Acceleron Becomes a Clinical-Stage Company

Adnexus Therapeutics

Adnexus Therapeutics Closes $27M Series B Funding

Adnexus Therapeutics Closes $27M Series B Funding

June 26, 2006

Series B Financing Led by Venrock will Advance Breakthrough New Product Class, AdNectins

Selecta Biosciences, Inc.

Selecta Biosciences Appoints Werner Cautreels, Ph.D., as Company's First CEO

Selecta Biosciences Appoints Werner Cautreels, Ph.D., as Company's First CEO

August 16, 2010

Watertown, Massachusetts, USA, August 16, 2010 – Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, announced today that Werner Cautreels, Ph.D. has been appointed as President and Chief Executive Officer. He has also been appointed to the company's Board of Directors. Dr.

Selecta Biosciences, Inc.

Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation

August 16, 2010

Targeted Synthetic Vaccine Particles (tSVP) Offer Potential for Increased Anti-Nicotine Efficacy to Increase Success of Smoking Cessation

Morphotek, Inc.

Morphotek announces successful development of antibody cell line for Abgenix

Morphotek announces successful development of antibody cell line for Abgenix

December 16, 2003

Exton, PA - December 16, 2003 - Morphotek Inc. announced today that Abgenix, Inc. of Fremont, CA has confirmed the development of an antibody-producing cell line from the companies' research collaboration. The development resulted in an undisclosed milestone payment to Morphotek.

LS9

LS9 Announces Major Scientific Breakthrough Leading to Scalable Production of Low-cost Sustainable Fuels

LS9 Announces Major Scientific Breakthrough Leading to Scalable Production of Low-cost Sustainable Fuels

July 29, 2010

The full LS9 press release is included below. You can find additional coverage of the announcement on:

Venture Beat: LS9 may have just solved biofuels’ scaling problem
Xconomy.com: LS9 Shows Recipe For $50 Oil: Genes That Convert Sugar to Diesel in One Step

Helicos BioSciences Corporation

Helicos Announces Nature Publication on First Evidence of RNA Copying Mechanisms in Human Cells

Helicos Announces Nature Publication on First Evidence of RNA Copying Mechanisms in Human Cells

July 29, 2010

Joint Research with University of Pittsburgh School of Medicine, Integromics, Inc. and the University of Geneva Medical School

Everyday Solutions, Inc.

Everyday Solutions, Inc. Appoints Tom Liebermann Executive Chairman Role

Everyday Solutions, Inc. Appoints Tom Liebermann Executive Chairman Role

July 29, 2010

Concord, MA USA – July 29, 2010 – Everyday Solutions, Inc., the leading provider of integrated solutions for managing School Transportation Information, announced today that Tom Liebermann has been appointed to the role of Executive Chairman of the Board. Mr. Liebermann will lead Everyday Solutions’ Board of Directors, help shape the strategic direction for the company and act as a sounding board for the executive management team on tactical and operational opportunities.